Replication-competent recombinant herpes simplex virus type 1 (HSV-1) comprising deletions in the ICP6 and IR regions

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anticancer HSV-1 viruses face limitations due to low therapeutic efficacy and challenges in genetic modification due to the absence of essential genes for viral replication and a large genome size, making it difficult to develop effective recombinant vectors for cancer treatment.

Innovation Solution

A recombinant HSV-1 vector is developed with deletions in the ICP6 and IR regions, allowing for the insertion of large foreign genes and enhancing cancer cell selectivity and viral stability, while maintaining the ability to replicate in cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the HSV-1 genome is used for cancer treatment, then oncolytic activity is achieved, but therapeutic efficacy is limited due to low replication capability

Engineering Contradiction:

Improveoncolytic activityVSAvoidtherapeutic efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent extracts and removes the ICP6 gene from the HSV-1 genome to create a replication-competent oncolytic virus. By taking out this specific gene, the virus maintains its ability to replicate in cancer cells while improving therapeutic efficacy and reducing limitations of conventional HSV-1-based treatments

Inventive Principle:

Principle #2Taking out (Extraction)

2Ease of manufacture

If genes are deleted from HSV-1 to enable genetic modification, then ease of genetic modification is improved, but viral replication capability deteriorates

Engineering Contradiction:

Improvegenetic modification capabilityVSAvoidviral replication capability

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent converts the potential harm of gene deletion (loss of replication capability) into a benefit by selectively removing the ICP6 gene, which creates space for genetic modification while maintaining replication competence through compensatory mechanisms that allow the virus to replicate effectively in cancer cells

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Adaptability or versatility

If the HSV-1 genome is used as a vector, then capacity for genetic modification is improved, but device complexity increases due to large genome size

Engineering Contradiction:

Improvegenetic modification capacityVSAvoidgenome size

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent extracts and removes the ICP6 gene region from the HSV-1 genome, creating a deletion that provides additional space for inserting therapeutic genes. This extraction reduces genome complexity while maintaining or enhancing the vector's capacity for genetic modification and cancer treatment

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS12600955B1Replication-competent recombinant herpes simplex virus type 1 (HSV-1) comprising deletions in the ICP6 and IR regions

Publication Date: 2026.04.14 SUNG KWANG MEDICAL FOUND

AI summary

A recombinant herpes simplex virus type 1 (HSV-1), a recombinant HSV-1 vector, and a method of preparing the recombinant HSV-1, may enable easy genetic modification, as a relatively large foreign gene may be inserted or various foreign genes may be inserted simultaneously, as ICP6 and IR regions are simultaneously deleted. These may be used in cancer treatment as an oncolytic virus that is safe, while having an excellent effect in killing cancer cells.